Redefining efficacy of antihypertensive therapies beyond blood pressure reduction - The role of angiotensin II antagonists

International Journal of Clinical Practice

Volumn 59, Issue 2, 2005, Pages 214-224

  Conlin, Paul R ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Amlodipine; Angiotensin II antagonists; Atenolol; Candesartan; Cardiovascular disease; Hypertension; Irbesartan; Losartan; Outcomes; Valsartan

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; ANGIOTENSIN II ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN; HYDROCHLOROTHIAZIDE; IRBESARTAN; LISINOPRIL; LOSARTAN; RAMIPRIL; TELMISARTAN; THIAZIDE DIURETIC AGENT; VALSARTAN;

ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DIABETES MELLITUS; DRUG EFFICACY; DRUG MECHANISM; DRUG USE; EVIDENCE BASED MEDICINE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; MEDICAL DECISION MAKING; MORBIDITY; MORTALITY; OUTCOMES RESEARCH; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; HUMANS; HYPERTENSION; PRACTICE GUIDELINES; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS; RISK REDUCTION BEHAVIOR; TREATMENT OUTCOME;

EID: 14744301979     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2005.00446.x     Document Type: Review

References (65)

1. Chobanian AV, Bakris GL, Black HR et al. The Seventh Report of the Joint National Committee on Prevention, Detection Evaluation and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560-72.
2. Wolf-Maier K, Cooper RS, Banegas JR et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA 2003; 289: 2363-9.
3. European Society of Hypertension-European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011-53.
4. Brenner BM, Cooper ME, de Zeeuw D. et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-9.
5. Dahlof B, Devereux RB, Kjeldsen SE. et al. Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995-1003.
6. Julius S. Five decades of antihypertensive treatment: the unresolved issues. J Hypertens Suppl 2000; 18: S3-7.
7. Weber M. Guidelines for assessing outcomes of antihypertensive treatment. Am J Cardiol 1999; 84: 2K-4K.
8. Fleming TR, DeMets DL. Surrogate end points in clinical trials: are we being misled? Ann Intern Med 1996; 125: 605-13.
9. Benedict CR. Evidence-based approach to managing hypertension and the need for target-organ protection. In: European Union of General Practitioners Reference Book 1999/2000. London: Kensington Publications Ltd, 1999: 1-4.
10. Furberg CD. Class effects and evidence-based medicine. Clin Cardiol 2000; 23: IV15-19.
11. Carter BL, Ernst ME, Cohen JD. Hydrochlorothiazide versus chlorthalidone: evidence supporting their interchangeability. Hypertension 2004; 43: 4-9.
12. ALLHAT officers and coordinators for the ALLHAT collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288 2981-97.
13. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA 1991; 265: 3255-64.
14. Cutler JA, MacMahon SW, Furberg CD. Controlled clinical trials of drug treatment for hypertension. A review. Hypertension 1989; 13: 136-144.
15. Psaty BM, Smith NL, Siscovick DS et al. Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis. JAMA 1997; 277: 739-45.
16. Collins R, MacMahon S. Blood pressure, antihypertensive drug treatment and the risks of stroke and of coronary heart disease. Br Med 1994; 50: 272-98.
17. Wing LM, Reid CM, Ryan P et al. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2003; 348: 583-92.
18. Brown MJ, Palmer CR, Castaigne A et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000; 356: 366-72.
19. Hansson L, Lindholm LH, Niskanen L et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999; 353: 611-6.
20. Hansson L, Lindholm LH, Ekbom T et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999; 354: 1751-6.
21. Hansson L, Lithell H, Skoog I et al. Study on COgnition and Prognosis in the Elderly (SCOPE): baseline characteristics. Blood Press 2000; 9: 146-51.
22. Dahlof B, Devereux R, de Faire U et al. The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study Group. Am J Hypertens 1997; 10: 705-13.
23. American Heart Association. Heart Disease and Stroke Statistics, 2003 Update. Dallas, Texas: American Heart Association, 2003.
24. Hart RG. Atrial fibrillation and stroke prevention. N Engl J Med 2003; 349: 1015-6.
25. Wachtell K, Hornestram B, Lehto M et al. Cardiovascular mortality and morbidity in hypertensive patients with atrial fibrillation: the LIFE study. J Am Coll Cardiol 2003; 41: 276A.
26. Dahlof B, Zanchetti A, Diez J et al. Effects of losartan and atenolol on left ventricular mass and neurohormonal profile in patients with essential hypertension and left ventricular hypertrophy. J Hypertens 2002; 20: 1855-64.
27. Ibsen H, Olsen MH, Wachtell K et al. Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in patients with hypertension and left ventricular hypertrophy? The LIFE Study. J Hypertens 2003; 21 (Suppl. 4): S68 [Abstract].
28. Burnier M, Pechere-Bertschi A, Nussberger J et al. Studies of the renal effects of angiotensin II receptor blockade: the confounding factor of acute water loading on the action of vasoactive systems. Am J Kidney Dis 1995; 26: 108-15.
29. Hamada T, Hisatome I, Kinugasa Y et al. Effect of the angiotensin II receptor antagonist losartan on uric acid and oxypurine metabolism in healthy subjects. Intern Med 2002; 41: 793-7.
30. Minghelli G, Seydoux C, Goy JJ et al. Uricosuric effect of the angiotensin II receptor antagonist losartan in heart transplant recipients. Transplantation 1998; 66: 268-71.
31. Sasaki M, Fujimura A, Harada K et al. Clinical pharmacology of multiple-dose losartan, an angiotensin II receptor antagonist, in patients with essential hypertension. J Clin Pharmacol 1996; 36 403-8.
32. Hoieggen A, Alderman MH, Kjeldsen SE et al. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int 2004; 65: 1041-9.
33. Opie LH, Schall R. Old antihypertensives and new diabetes. J Hypertens 2004; 22: 1453-8.
34. Gress TW, Nieto FJ, Shahar E et al. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study. N Engl J Med 2000; 342: 905-12.
35. Lithell H, Hansson L, Skoog I et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003; 21: 875-86.
36. Staessen JA, Gasowski J, Wang JG et al. Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet 2000; 355: 865-72.
37. Lithell H, Hansson L, Skoog I et al. The Study on COgnition and Prognosis in the Elderly (SCOPE): outcomes in patients not receiving add-on therapy after randomization. J Hypertens 2004; 22: 1605-12.
38. Julius S, Kjeldsen SE, Brunner H et al. VALUE trial: long-term blood pressure trends in 13,449 patients with hypertension and high cardiovascular risk. Am J Hypertens 2003; 16: 544-8.
39. Julius S, Kjeldsen SE, Weber M et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomized trial. Lancet 2004; 363: 2049-51.
40. Weber M. The telmisartan Programme of Research tO show Telmisartan End-organ proteCTION (PROTECTION) programme. J Hypertens 2003; 21 (Suppl. 6): S37-46.
41. Fukui T, Rahman M, Hayashi K et al. Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial of cardiovascular events in high-risk hypertensive patients: rationale, design, and methods. Hypertens Res 2003; 26: 979-90.
42. Lewis EJ, Hunsicker LG, Rodby RA. A clinical trial in type 2 diabetic nephropathy. Am J Kidney Dis 2001; 38: S191-S194.
43. Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 20 (345): 851-60.
44. Lewis EJ. The role of angiotensin II receptor blockers in preventing the progression of renal disease in patients with type 2 diabetes. Am J Hypertens 2002; 15: 123S-8S.
45. Rodby RA, Rohde RD, Clarke WR et al. The Irbesartan type II diabetic nephropathy trial: study design and baseline patient characteristics. For the Collaborative Study Group. Nephrol Dial Transplant 2000; 15: 487-97.
46. Ritz E. Nephropathy in type 2 diabetes. J Intern Med 1999; 245: 111-26.
47. Alderman MH. Allhat and beyond. Am J Hypertens 2003; 16: 512-4.
48. Flack JM, Nasser SA for Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. Curr Hypertens Rep 2003; 5: 189-91.
49. Beevers DG, Lee KW, Lip GY. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT): ALL predictable, and no big surprise out of a HAT? J Hum Hypertens 2003; 17: 367-72.
50. Laragh JH, Sealey JE. Relevance of the plasma renin hormonal control system that regulates blood pressure and sodium balance for correctly treating hypertension and for evaluating ALLHAT. Am J Hypertens 2003; 16: 407-15.
51. Nilsson P. Conclusions in an Australian trial differ from those in the ALLHAT trial: ACE inhibitors are more effective than thiazides in elderly men with hypertension. Lakartidningen 2003; 100: 1118-20.
52. Okereke CE, Messerli FH. Efficacy and safety of angiotensin II receptor blockers in elderly patients with mild to moderate hypertension. Am J Geriatr Cardiol 2001; 10: 42-9.
53. Mazzolai L, Burnier M. Comparative safety and tolerability of angiotensin II receptor antagonists. Drug Saf 1999; 21: 23-33.
54. Benedict CR. Safe and effective management of hypertension with fixed-dose combination therapy: focus on losartan plus hydrochlorothiazide. Int J Clin Pract 2000; 54: 48-54.
55. Conlin PR, Gerth WC, Fox J et al. Four-Year persistence patterns among patients initiating therapy with the angiotensin II receptor antagonist losartan versus other antihypertensive drug classes. Clin Ther 2001; 23: 1999-2010.
56. Bloom BS. Continuation of initial antihypertensive medication after 1 year of therapy. Clin Ther 1998; 20: 671-81.
57. Williams B, Poulter NR, Brown MJ et al. British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary. BMJ 2004; 328: 634-40.
58. Devereux R, Wachtell K, Gerdts E et al. Regression of hypertensive left ventricular hypertrophy: treatment effects and prognostic implications in the LIFE trial. J Hypertens 2002; 20 (Suppl. A): 55.
59. Olsen MH, Wachtell K, Neland K, Rokkedal J, Ibsen H, Dige-Petersen H. The effect of losartan versus atenolol on carotid artery hypertrophy in essential hypertension. A LIFE Substudy. Circulation 2002; 106 (19): II-574.
60. Strawn WB, Chappell MC, Dean RH et al. Inhibition of early atherogenesis by losartan in monkeys with diet-induced hypercholesterolemia. Circulation 2000; 101: 1586-93.
61. Schiffrin EL, Park JB, Intengan HD et al. Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan. Circulation 2000; 101: 1653-9.
62. Guerra-Cuesta JI, Monton M, Rodriguez-Feo JA et al. Effect of losartan on human platelet activation. J Hypertens 1999; 17: 447-52.
63. Kramer C, Sunkomat J, Witte J et al. Angiotensin II receptor-independent antiinflammatory and antiaggregatory properties of losartan: role of the active metabolite EXP3179. Circ Res 2002; 19 (90): 770-6.
64. Levy PJ, Yunis C, Owen J et al. Inhibition of platelet aggregability by losartan in essential hypertension. Am J Cardiol 2000; 86: 1188-92.
65. Erdem Y, Usalan C, Haznedaroglu IC et al. Effects of angiotensin converting enzyme and angiotensin II receptor inhibition on impaired fibrinolysis in systemic hypertension. Am J Hypertens 1999; 12: 1071-6.